Lu, Ming

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 2,932

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 855

Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

Fleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 448

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid

Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 401

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 357

Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 270

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., et al. (2022) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 210

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

AV45-A11 Study Group, Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., et al. (2014) · Molecular Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 195

Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.

Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 79

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials

Lu, M., Pontecorvo, M. J., Devous, M. D., Arora, A. K., Galante, N., McGeehan, A., Devadanam, C., Salloway, S. P., Doraiswamy, P. M., Curtis, C., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 56

TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway, S., Pain, A., Lee, E., Papka, M., Ferguson, M. B., Wang, H., Hu, H., Lu, M., Oru, E., Ardayfio, P. A., et al. (2025) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 37

1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

Mintun, M., Ritchie, C., Solomon, P., Sims, J. R., Salloway, S., Hansson, O., Apostolova, L. G., Zimmer, J. A., Evans, C. D., Lu, M., et al. (2024) · Age and Ageing

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 8

[P2–383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER's DISEASE PATHOLOGY: A PILOT CLINICO‐PATHOLOGICAL STUDY

Siderowf, A. D., Dirk Keene, C., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M., Kennedy, I., Joshi, A. D., Pontecorvo, M. J., et al. (2017) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 2